Andres Acosta1, Michael Camilleri2, Irene Busciglio3, Amy Boldingh4, Alfred D Nelson5, Duane Burton6. 1. Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Charlton 8-110, 200 First St. S.W., Rochester, MN, 55905, USA. acostacardenas.andres@mayo.edu. 2. Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Charlton 8-110, 200 First St. S.W., Rochester, MN, 55905, USA. camilleri.michael@mayo.edu. 3. Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Charlton 8-110, 200 First St. S.W., Rochester, MN, 55905, USA. busciglio.irene@mayo.edu. 4. Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Charlton 8-110, 200 First St. S.W., Rochester, MN, 55905, USA. boldingh.amy@mayo.edu. 5. Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Charlton 8-110, 200 First St. S.W., Rochester, MN, 55905, USA. nelson.alfred@mayo.edu. 6. Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Charlton 8-110, 200 First St. S.W., Rochester, MN, 55905, USA. burton.duane@mayo.edu.
Abstract
BACKGROUND: The pentapeptide ghrelin agonist, relamorelin, accelerates colonic transit in patients with chronic constipation (CC). In a murine model, relamorelin decreased excitability of colonic circular smooth muscle cells and colonic intraluminal pressure. AIM: To determine short-term effects of relamorelin on colonic motility measured by barostat and multilumen manometry in CC. METHODS: In a placebo-controlled, single-dose, double-blind, randomized study in patients with CC, we investigated the motor effects of relamorelin, 100 μg, SQ (12 patients) compared to placebo SQ (six patients). A motility-barostat balloon assembly was used to measure colonic compliance; tone and phasic pressure activity were measured before and after a 1000-kcal milkshake meal (administered ~60 min post-medication). Overall "background" phasic pressure activity was assessed by: average amplitude and motility index (MI = ln[sum amplitudes × #contractions + 1]) over defined periods. High-amplitude propagating contractions (HAPCs) were characterized by amplitude >75 mmHg and propagating contractions >50 mmHg; both were propagated over at least 10 cm. Postprandial HAPCs were the primary end point. The study sample had 80% power to detect an increase of 3.3 HAPCs in the hour post-meal. RESULTS:Relamorelin, 100 μg, significantly induced more pre-meal propagated contractions [PCs of either >50 or >75 mmHg] compared to placebo (p < 0.05). Relamorelin also induced more post-meal PCs >50 or >75 mmHg than placebo. Relamorelin did not significantly alter colonic compliance, fasting or postprandial phasic pressure activity (20 min pre-meal fasting MI) or tone, and 60 min postprandial phasic pressure amplitude or MI, or tone. CONCLUSIONS:Relamorelin stimulates propagated colonic contractions without alteration of background irregular contractions in CC. ClinicalTrial.Gov registration number: NCT 01781104.
RCT Entities:
BACKGROUND: The pentapeptide ghrelin agonist, relamorelin, accelerates colonic transit in patients with chronic constipation (CC). In a murine model, relamorelin decreased excitability of colonic circular smooth muscle cells and colonic intraluminal pressure. AIM: To determine short-term effects of relamorelin on colonic motility measured by barostat and multilumen manometry in CC. METHODS: In a placebo-controlled, single-dose, double-blind, randomized study in patients with CC, we investigated the motor effects of relamorelin, 100 μg, SQ (12 patients) compared to placebo SQ (six patients). A motility-barostat balloon assembly was used to measure colonic compliance; tone and phasic pressure activity were measured before and after a 1000-kcal milkshake meal (administered ~60 min post-medication). Overall "background" phasic pressure activity was assessed by: average amplitude and motility index (MI = ln[sum amplitudes × #contractions + 1]) over defined periods. High-amplitude propagating contractions (HAPCs) were characterized by amplitude >75 mmHg and propagating contractions >50 mmHg; both were propagated over at least 10 cm. Postprandial HAPCs were the primary end point. The study sample had 80% power to detect an increase of 3.3 HAPCs in the hour post-meal. RESULTS:Relamorelin, 100 μg, significantly induced more pre-meal propagated contractions [PCs of either >50 or >75 mmHg] compared to placebo (p < 0.05). Relamorelin also induced more post-meal PCs >50 or >75 mmHg than placebo. Relamorelin did not significantly alter colonic compliance, fasting or postprandial phasic pressure activity (20 min pre-meal fasting MI) or tone, and 60 min postprandial phasic pressure amplitude or MI, or tone. CONCLUSIONS:Relamorelin stimulates propagated colonic contractions without alteration of background irregular contractions in CC. ClinicalTrial.Gov registration number: NCT 01781104.
Authors: Smita L S Halder; G Richard Locke; Cathy D Schleck; Alan R Zinsmeister; L Joseph Melton; Nicholas J Talley Journal: Gastroenterology Date: 2007-06-20 Impact factor: 22.682
Authors: B N I Floyd; M Camilleri; V Andresen; T Esfandyari; I Busciglio; A R Zinsmeister Journal: Neurogastroenterol Motil Date: 2007-10-25 Impact factor: 3.598
Authors: L Trudel; C Tomasetto; M C Rio; M Bouin; V Plourde; P Eberling; P Poitras Journal: Am J Physiol Gastrointest Liver Physiol Date: 2002-06 Impact factor: 4.052
Authors: Y Date; M Kojima; H Hosoda; A Sawaguchi; M S Mondal; T Suganuma; S Matsukura; K Kangawa; M Nakazato Journal: Endocrinology Date: 2000-11 Impact factor: 4.736
Authors: Silvia Delgado-Aros; Heather J Chial; Michael Camilleri; Lawrence A Szarka; Frank T Weber; Jutta Jacob; Irene Ferber; Sanna McKinzie; Duane D Burton; Alan R Zinsmeister Journal: Am J Physiol Gastrointest Liver Physiol Date: 2003-04 Impact factor: 4.052
Authors: Andrea Shin; Michael Camilleri; Irene Busciglio; Duane Burton; Elizabeth Stoner; Patrick Noonan; Keith Gottesdiener; Steven A Smith; Adrian Vella; Alan R Zinsmeister Journal: Diabetes Care Date: 2012-09-06 Impact factor: 19.112
Authors: A D Nelson; M Camilleri; A Acosta; I Busciglio; S Linker Nord; A Boldingh; D Rhoten; M Ryks; D Burton Journal: Neurogastroenterol Motil Date: 2016-06-09 Impact factor: 3.598
Authors: Ruslan V Pustovit; Brid Callaghan; Mitchell T Ringuet; Nicole F Kerr; Billie Hunne; Ian M Smyth; Claudio Pietra; John B Furness Journal: Physiol Rep Date: 2017-08